Gilead Sciences Mergers and Acquisitions Summary

Life ScienceCompany

Gilead Sciences has acquired 21 companies, including 7 in the last 5 years. A total of 2 acquisitions came from private equity firms. It has also divested 3 assets.

Gilead Sciences’ largest acquisition to date was in 2020, when it acquired Immunomedics for $21.0B. It’s largest disclosed sale occurred in 2001, when it sold Gilead Oncology Business to OSI Pharmaceuticals for $200M. Gilead Sciences has acquired in 7 different US states, and 5 countries. The Company’s most targeted sectors include life science (96%) and chemicals (5%).

Join Mergr and gain access to Gilead Sciences’ M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

M&A Summary

  • M&A Total Activity24
    • M&A Buy Activity21
    • M&A Sell Activity3
  • Total Sectors Invested 2
  • Total Countries Invested 5
  • M&A Buy/Sell Connections 7
  • M&A Advisors 14

Gilead Sciences

Gilead Sciences, Inc.

333 Lakeside Drive,
Foster City, California 94404
United States,
(650) 574-3000
www.gilead.com

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was formed in 1987 and is Based in Foster City, California.


M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (1.2/yr) # 15 1 - - 5 - 21
vol $18.6B $11.9B $27.2B $57.7B
Sell (0.2/yr) # 2 1 - - - - 3
vol $206M $206M
  24

Most Recent M&A

Company Date Value Type
MYR GmbH 2020-12-10 1.3B EUR Add-on Acquisition
Bad Homburg, Germany · www.myr-pharma.com
Immunomedics, Inc. 2020-09-13 21.0B USD Add-on Acquisition
Morris Plains, New Jersey · www.immunomedics.com
Tizona Therapeutics, Inc. 2020-07-21 - Add-on Acquisition
South San Francisco, California · www.tizonatx.com
Pionyr Immunotherapeutics, Inc. 2020-06-20 - Stake Purchase
South San Francisco, California · www.pionyrtx.com
Forty Seven, Inc. 2020-03-02 4.9B USD Add-on Acquisition
Menlo Park, California · www.fortyseveninc.com
Kite Pharma, Inc. 2017-08-28 11.9B USD Add-on Acquisition
Santa Monica, California · www.kitepharma.com
Gilead Sciences, Inc. - GS-6637 2017-02-16 - Divestiture
Foster City, California
Nimbus Apollo, Inc. 2016-04-04 400M USD Divestiture
, United States
Epitherapeutics ApS 2015-05-06 65M USD Add-on Acquisition
Kobenhavn N, Denmark
Phenex Pharmaceuticals AG 2015-01-06 470M USD Add-on Acquisition
Ludwigshafen, Germany · www.phenex-pharma.com
View All >>

Business Unit M&A

Company Acquired Add-On/Sale Date #
Kite Pharma, Inc. 2017-08-28 Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility 2021-07-19 1
Santa Monica, California · www.kitepharma.com Gaithersburg, Maryland
Arresto Biosciences, Inc. 2010-12-20 Aeon Bioscience, Inc. 2010-12-20 1
Palo Alto, California · www.arresto.com Birmingham, Alabama · www.aeonbio.com

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 20 (95%) 57.6B (100%) 3 (100%) 206M (100%)
Chemicals 1 (5%) 130M (< 1%) - -
Total 21 $57.7B 3 $206M

By Geo

State/Country Buy Value Sell Value
United States 15 55.2B 3 206M
  California 6 18.4B 3 206M
  Washington 2 740M - -
  New Jersey 2 32.0B - -
  Colorado 2 3.1B - -
  North Carolina 1 464M - -
  Connecticut 1 120M - -
Canada 2 640M - -
  Ontario 1 510M - -
  Alberta 1 130M - -
Germany 2 1.8B - -
Denmark 1 65M - -
Ireland 1 47M - -
Domestic 15 (71%) 55.2B (96%) 3 (100%) 206M (100%)
Cross-border 6 (29%) 2.5B (4%) - -
Total 21 $57.7B 3 $206M

Top M&A Advisors

Financial Deals
Bank of America Merrill Lynch (BofA Securities)
4
J.P. Morgan Securities LLC
3
Goldman Sachs Investment Banking Division
2
Legal Deals
Skadden, Arps, Slate, Meagher & Flom LLP
3
Mayer Brown
1
Gibson, Dunn & Crutcher LLP
1

Deal Values

buy # Total
> $1B 7 $54.0B
$100M to $1B 10 $3.6B
< $100M 2 $112M
TOTAL $57.7B
Largest Immunomedics, Inc.
$21.0B (2020-09-13)
sell # Total
$100M to $1B 1 $200M
< $100M 1 $6M
TOTAL $206M
Largest Gilead Oncology Business
$200M (2001-12-21)

M&A Connections

Deals
Acquired from
Investor(s)
10%
2 (10%)
Strategic(s)
10%
2 (10%)
Divested to
Strategic(s)
100%
3 (100%)

 Subscribe to unlock this and 169,897
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.2K Private Equity Firms
  • 159K M&A Transactions
  • 166K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.3K M&A Advisors
    (Investment Banks and Law Firms)
  • 57K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.